The United States Federal Circuit confirms that isolated genes are patentable subject matter in the Myriad case

The Federal Circuit Court of Appeals in the United States has confirmed that isolated gene sequences are patentable which is good news for companies developing gene-based therapies and diagnostics (Association for Molecular Pathology (AMP) and ACLU v. USPTO and Myriad Genetics).  This judgement brings pratice in the US into line with many other jurisdications – including the UK Intellectual Property Office and the European Patent Office – on gene sequence patentability.

Further information can be found here.